SpliceBio Raises $135M to Advance Gene Therapy for Stargardt Disease

SpliceBio, a biotechnology company developing gene therapies, announced this Wednesday the closing of a $135 million Series B financing round (€118 million at current exchange rates).

The transaction was co-led by EQT Life Sciences and Sanofi Ventures and included participation from Roche Venture Fund and all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.

SpliceBio secures $135 million in Series B funding to advance SB-007, its lead gene therapy for Stargardt disease, and expand its pipeline into ophthalmology, neurology, and beyond

The funds raised by SpliceBio will support the clinical development of the company’s lead program, SB-007, a gene therapy targeting Stargardt disease, including the Phase 1/2 ASTRA clinical trial and the observational POLARIS clinical trial. SB-007 is the first gene therapy of its kind to receive clinical trial clearance from the US Food and Drug Administration (FDA) for Stargardt disease. SB-007 has also received clinical trial clearance from the UK Medicines and Healthcare products Regulatory Agency (MHRA ).

“The closing of this round represents a key milestone for SpliceBio as we advance the clinical development of SB-007 for Stargardt disease and expand our pipeline into ophthalmology, neurology, and other indications,” said Miquel Vilaperelló, CEO and co-founder of the company.

SpliceBio Matches Sanifit’s Legacy with €72.2M Boost for Stargardt Gene Therapy Development

Besides SpliceBio. the Balearic company Sanifit, specializing in the treatment of cardiovascular diseases, closed the largest round in the sector to date in 2019. The company raised €55.2 million, with Caixa Capital Risc being the largest investor.

The capital increase also included participation from the Madrid-based fund Columbus Venture Partners, the Barcelona-based Alta Life Sciences, as well as the Danish Lundbeckfonden Ventures and Ysios Capital. In parallel, it closed the capitalization of a €17 million loan, bringing the transaction total to €72.2 million.

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in elEconomista.es. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us